01—Abstract
Summary
Summary of the 10-Q filed November 6, 2025. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines Ltd. (ONC) reported a strong third quarter of 2025, with total revenues reaching $1.41 billiona, a significant 41% increase year-over-year.
This growth was primarily driven by robust performance in product revenue, which rose 40.4% to $1.395 billionb, led by a remarkable 50.8% surge in BRUKINSA® sales, now exceeding $1 billion globally for the quarter. The company also demonstrated improved profitability, swinging from a net loss in the prior year period to a net income of $124.8 million. This financial turnaround, coupled with an increase in R&D investment and SG&A expenses, reflects BeOne Medicines' strategic focus on expanding its commercial reach and advancing its promising oncology pipeline.
02—Key points
Key Highlights
- Total revenues increased by 41.0% to $1.41 billion for Q3 2025 compared to $1.00 billion in Q3 2024.
- Net product revenue grew by 40.4% to $1.395 billion for Q3 2025, primarily driven by BRUKINSA® sales.
- Global BRUKINSA® revenue reached $1.04 billion in Q3 2025, a 50.8% increase year-over-year.
- Income from operations turned positive, reaching $163.1 million in Q3 2025, a significant improvement from a loss of $120.3 million in Q3 2024.
- Net income was $124.8 million for Q3 2025, compared to a net loss of $121.4 million in Q3 2024.
- Diluted EPS (ADS) was $1.09 for Q3 2025, a substantial improvement from a loss of ($1.15) per ADS in Q3 2024.
- The company reported strong cash and cash equivalents, totaling $4.11 billion as of September 30, 2025, indicating a healthy liquidity position.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, BeOne Medicines Ltd. kept $0.09.
- Revenue$1.41B100.0%
- Cost of revenue−$196.5M13.9%
- Gross profit$1.22B86.1%
- Operating costs−$1.05B74.5%
- Operating income$163.1M11.5%
- Interest, other & tax−$38.3M2.7%
- Net income$124.8M8.8%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 6, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $1.41B$1.00B | +41.0% |
| Gross Profit | $1.22B$831.14M | +46.3% |
| R&D Expenses | $523.66M$496.18M | +5.5% |
| SG&A Expenses | $529.00M$455.22M | +16.2% |
| Operating Expenses | $1.05B$951.40M | +10.6% |
| Operating Income | $163.11M-$120.27M | +235.6% |
| Interest Expense | $12.65M$14.31M | −11.6% |
| Net Income | $124.84M-$121.35M | +202.9% |
| EPS (Basic) | $0.09$-0.09 | +200.0% |
| EPS (Diluted) | $0.08$-0.09 | +188.9% |
| Shares Outstanding (Basic) | 1.43B1.38B | +4.1% |
| Shares Outstanding (Diluted) | 1.49B1.38B | +8.1% |
05—Questions
Frequently Asked Questions
What was the primary driver of BeOne Medicines' revenue growth in Q3 2025?
The primary driver of BeOne Medicines' revenue growth in Q3 2025 was the significant increase in net product revenue, which rose by 40.4% to $1.395 billion. This growth was predominantly fueled by the strong performance of BRUKINSA®, which saw its global revenue increase by 50.8% year-over-year to $1.04 billion.
How did BeOne Medicines' profitability change in Q3 2025 compared to Q3 2024?
BeOne Medicines demonstrated a significant improvement in profitability. The company swung from a net loss of $121.4 million in Q3 2024 to a net income of $124.8 million in Q3 2025. This turnaround was reflected in a positive income from operations of $163.1 million, a substantial improvement from a loss of $120.3 million in the prior year period.
What is the company's current liquidity position?
BeOne Medicines maintains a strong liquidity position, with cash, cash equivalents, and restricted cash totaling $4.11 billion as of September 30, 2025. This robust cash balance provides significant financial flexibility for ongoing operations and strategic investments.
What impact did the sale of future royalties have on the company's financials?
On August 25, 2025, BeOne Medicines entered into an agreement to sell royalty rights for IMDELLTRA® for up to $950 million, receiving an upfront payment of $885 million. This transaction significantly boosted the company's cash position but is recorded as a financing liability, with repayment tied to future royalty revenues. The liability was $885 million as of September 30, 2025, with $5.58 million in interest expense accrued in Q3 2025.
06—Continue